ANALYSIS OF NOMENCLATURE OF HYPOTENSIVE MEDICINES USED IN CHILDREN AND ADOLESCENTS
Objective. Analysis of the range of antihypertensive drugs recommended for the treatment and prevention of hypertension in children and adolescents. Methods. The analysis of the nomenclature of antihypertensive drugs used for the treatment and prevention of arterial hypertension in children and adolescents was carried out. The study was conducted by the method of content analysis of drugs registered and authorized for circulation in the Russian Federation. Results. Cardiovascular diseases are the main cause of early disability and death among the population of many countries [1]. Arterial hypertension occurs in 40% of the adult population. At the same time, 18.5% of men and 30.4% of women suffering from arterial hypertension had increased blood pressure in childhood or adolescence [5]. For the treatment of hypertension in children and adolescents, 5 main groups are recommended: 1) angiotensin converting enzyme inhibitors; 2) angiotensin receptor blockers; 3) beta-blockers; 4) calcium channel blockers (dihydropyridine); 5) thiazide diuretics. Preparations of these pharmacological groups registered in the territory of the Russian Federation are manufactured under 641 trade names in 35 countries of the world. Russia's share in the production of the above groups of drugs is 303 (47%) trade names. The share of foreign manufacturers is 338 (53%) trade names. The drugs of the studied groups are mainly produced in the form of tablets counting 367 (57%) trade names. Conclusions. In 2003, the first recommendations of the All-Russian Scientific Society of Cardiology and the Association of Pediatric Cardiologists of Russia were created in connection with the urgent need to determine the principles of diagnosis, treatment and prevention of hypertension in children (1-12 years old) and adolescents (13-18 years old). Currently, one of the main and relevant documents is the Clinical Recommendations of “Arterial Hypertension in Children”, developed by the professional association of pediatric cardiologists of Russia and the Union of Pediatricians of Russia and approved by the Ministry of Health of the Russian Federation in 2016. The use of antihypertensive drugs in children and adolescents is complicated by an insufficient scientific database on the effectiveness of drugs and their pharmacokinetics in children, as well as the lack of recommendations from drug manufacturers on the use of many drugs in childhood and adolescence.